Syros Pharmaceuticals Inc received notice from Pfizer Inc PFE, as successor to Global Blood Therapeutics Inc, exercising its right to terminate the License and Collaboration Agreement dated December ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies ...
Every time Joanna publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate. The trial assessed tamibarotene in ...
Une soixantaine d’Italiens, dont quatre parlementaires, se trouvent à bord de la Global Sumud Flotilla, qui comprend une ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback